{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:18:41Z","timestamp":1788866321524,"version":"build-2803163510"},"reference-count":216,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["2018-21790"],"award-info":[{"award-number":["2018-21790"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","award":["2016-02365049"],"award-info":[{"award-number":["2016-02365049"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Medullary thyroid carcinoma (MTC) is a neuroendocrine malignant tumor originating from parafollicular C-cells producing calcitonin. Most of cases (75%) are sporadic while the remaining (25%) are hereditary. In these latter cases medullary thyroid carcinoma can be associated (multiple endocrine neoplasia type IIA and IIB) or not (familial medullary thyroid carcinoma), with other endocrine diseases such as pheochromocytoma and\/or hyperparathyroidism. RET gene point mutation is the main molecular alteration involved in MTC tumorigenesis, both in sporadic and in hereditary cases. Total thyroidectomy with prophylactic\/therapeutic central compartment lymph nodes dissection is the initial treatment of choice. Further treatments are needed according to tumor burden and rate of progression. Surgical treatments and local therapies are advocated in the case of single or few local or distant metastasis and slow rate of progression. Conversely, systemic treatments should be initiated in cases with large metastatic and rapidly progressive disease. In this review, we discuss the details of systemic treatments in advanced and metastatic sporadic MTC, focusing on multikinase inhibitors, both those already used in clinical practice and under investigation, and on emerging treatments such as highly selective RET inhibitors and radionuclide therapy.<\/jats:p>","DOI":"10.3389\/fendo.2022.864253","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T08:36:22Z","timestamp":1648629382000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine"],"prefix":"10.3389","volume":"13","author":[{"given":"Antonio","family":"Matrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Gambale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/95.3.300","article-title":"Medullary Thyroid Cancer. An Immunohistochemical and Humoral Study Using Six Separate Antigens","volume":"95","author":"Pacini","year":"1991","journal-title":"Am J Clin Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2016.04.053","article-title":"Trends in the Presentation, Treatment, and Survival of Patients With Medullary Thyroid Cancer Over the Past 30 Years","volume":"161","author":"Randle","year":"2017","journal-title":"Surgery"},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/02841869009089985","article-title":"Incidence of Sporadic and Familial Medullary Thyroid Carcinoma in Sweden 1959 Through 1981. A Nationwide Study in 126 Patients. Swedish MCT Study Group","volume":"29","author":"Bergholm","year":"1990","journal-title":"Acta Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1067\/mhn.2003.2","article-title":"A Population-Based Analysis of Survival Factors in Differentiated and Medullary Thyroid Carcinoma","volume":"128","author":"Bhattacharyya","year":"2003","journal-title":"Otolaryngology\u2013head Neck Surgery: Off J Am Acad Otolaryngol-Head Neck Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0959","article-title":"The Prevalence of Occult Medullary Thyroid Carcinoma at Autopsy","volume":"96","author":"Valle","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0169","article-title":"Thyroid Carcinoma, Version 2.2014","volume":"12","author":"Tuttle","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013","volume":"317","author":"Lim","year":"2017","journal-title":"Jama"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/genes10090698","article-title":"Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on the Prevalence of Germline RET Mutations","volume":"10","author":"Elisei","year":"2019","journal-title":"Genes (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET Proto-Oncogene Are Associated With MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum Mol Genet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1995.tb01208.x","article-title":"Genotype-Phenotype Correlation in Multiple Endocrine Neoplasia Type 2: Report of the International RET Mutation Consortium","volume":"238","author":"Mulligan","year":"1995","journal-title":"J Intern Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/363458a0","article-title":"Germ-Line Mutations of the RET Proto-Oncogene in Multiple Endocrine Neoplasia Type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/705036","article-title":"Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2","volume":"2012","author":"Romei","year":"2012","journal-title":"J Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02102","article-title":"Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases","volume":"104","author":"Elisei","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10228","article-title":"Very Early Detection of RET Proto-Oncogene Mutation Is Crucial for Preventive Thyroidectomy in Multiple Endocrine Neoplasia Type 2 Children: Presence of C-Cell Malignant Disease in Asymptomatic Carriers","volume":"94","author":"Sanso","year":"2002","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1410468","article-title":"Early or Prophylactic Thyroidectomy in MEN 2\/FMTC Gene Carriers: Results in 71 Thyroidectomized Patients. The French Calcitonin Tumours Study Group (GETC)","volume":"141","author":"Niccoli-Sire","year":"1999","journal-title":"Eur J Endocrinol\/European Fed Endocrine Societies"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012915","article-title":"Early Malignant Progression of Hereditary Medullary Thyroid Cancer","volume":"349","author":"Machens","year":"2003","journal-title":"New Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.76","article-title":"Anaplastic Thyroid Carcinoma: From Clinicopathology to Genetics and Advanced Therapies","volume":"13","author":"Molinaro","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19841015)54:8<1629::aid-cncr2820540826>3.0.co;2-m","article-title":"Mortality From Thyroid Carcinoma in Malmo, Sweden 1960-1977. A Clinical and Pathologic Study of 38 Fatal Cases","volume":"54","author":"Christensen","year":"1984","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1998.8.517","article-title":"Medullary Thyroid Carcinoma: Clinical Features and Long-Term Follow-Up of Seventy-Eight Patients Treated Between 1969 and 1986","volume":"8","author":"Girelli","year":"1998","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2017.3555","article-title":"Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma","volume":"153","author":"Kuo","year":"2018","journal-title":"JAMA Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24126","article-title":"Changing Trends in the Clinicopathological Features and Clinical Outcomes of Medullary Thyroid Carcinoma","volume":"113","author":"Kwon","year":"2016","journal-title":"J Surg Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-019-01764-3","article-title":"Cure and Survival of Sporadic Medullary Thyroid Carcinoma Following Systematic Preoperative Calcitonin Screening","volume":"404","author":"Torresan","year":"2019","journal-title":"Langenbecks Arch Surg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-017-4321-z","article-title":"Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience","volume":"42","author":"Torresan","year":"2018","journal-title":"World J Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1996.6.305","article-title":"Medullary Thyroid Cancer: Analyses of Survival and Prognostic Factors and the Role of Radiation Therapy in Local Control","volume":"6","author":"Brierley","year":"1996","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0564","article-title":"Survival and Long-Term Biochemical Cure in Medullary Thyroid Carcinoma in Denmark 1997-2014: A Nationwide Study","volume":"29","author":"Mathiesen","year":"2019","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-6196(12)60923-9","article-title":"Medullary Thyroid Carcinoma: Clinicopathologic Features and Long-Term Follow-Up of 65 Patients Treated During 1946 Through 1970","volume":"67","author":"Gharib","year":"1992","journal-title":"Mayo Clinic Proc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010094","article-title":"Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma","volume":"13","author":"Matrone","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(20000301)88:5<1139::aid-cncr26>3.0.co;2-z","article-title":"Medullary Thyroid Carcinoma: Clinical Characteristics, Treatment, Prognostic Factors, and a Comparison of Staging Systems","volume":"88","author":"Kebebew","year":"2000","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030550","article-title":"Impact of Routine Measurement of Serum Calcitonin on the Diagnosis and Outcome of Medullary Thyroid Cancer: Experience in 10,864 Patients With Nodular Thyroid Disorders","volume":"89","author":"Elisei","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2008.09.008","article-title":"Routine Serum Calcitonin Measurement in the Evaluation of Thyroid Nodules","volume":"22","author":"Elisei","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1530\/EJE-21-0313","article-title":"Ultrasound Features and Risk Stratification Systems to Identify Medullary Thyroid Carcinoma","volume":"185","author":"Matrone","year":"2021","journal-title":"Eur J Endocrinol\/European Fed Endocrine Societies"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4158\/EP13143.OR","article-title":"Fine Needle Aspiration and Medullary Thyroid Carcinoma: The Risk of Inadequate Preoperative Evaluation and Initial Surgery When Relying Upon FNAB Cytology Alone","volume":"19","author":"Essig","year":"2013","journal-title":"Endocrine Practice: Off J Am Coll Endocrinol Am Assoc Clin Endocrinologists"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12563","article-title":"Detection Rate of FNA Cytology in Medullary Thyroid Carcinoma: A Meta-Analysis","volume":"82","author":"Trimboli","year":"2015","journal-title":"Clin Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26550","article-title":"Limitations of Preoperative Cytology for Medullary Thyroid Cancer: Proposal for Improved Preoperative Diagnosis for Optimal Initial Medullary Thyroid Carcinoma Specific Surgery","volume":"43","author":"Workman","year":"2021","journal-title":"Head Neck"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0042","article-title":"Medullary Thyroid Carcinoma: Management of Lymph Node Metastases","volume":"8","author":"Moley","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0574","article-title":"Medullary Thyroid Carcinoma Beyond Surgery: Advances, Challenges, and Perspectives","volume":"26","author":"Ceolin","year":"2019","journal-title":"Endocrine-Related Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1714","article-title":"Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study","volume":"93","author":"Elisei","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-016-9394-8","article-title":"Flushing in (Neuro)Endocrinology","volume":"17","author":"Hannah-Shmouni","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2017.02.009","article-title":"Targeted Therapy in Thyroid Cancer: State of the Art","volume":"29","author":"Valerio","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ecl.2018.11.006","article-title":"Management of Medullary Thyroid Cancer","volume":"48","author":"Viola","year":"2019","journal-title":"Endocrinol Metab Clinics North America"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2021.47","article-title":"Systemic Treatment of Advanced, Metastatic, Medullary Thyroid Carcinoma","volume":"7","author":"Matrone","year":"2021","journal-title":"J Cancer Metastasis Treat"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03666.x","article-title":"Calcitonin and Carcinoembryonic Antigen Doubling Times as Prognostic Factors in Medullary Thyroid Carcinoma: A Structured Meta-Analysis","volume":"72","author":"Meijer","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1530\/EJE-15-0304","article-title":"Elevated Level of Serum Carbohydrate Antigen 19.9 as Predictor of Mortality in Patients With Advanced Medullary Thyroid Cancer","volume":"173","author":"Elisei","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0351","article-title":"F-18-Dopa Positron Emission Tomography\/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent\/Recurrent Disease of Medullary Thyroid Cancer Patients","volume":"29","author":"Terroir","year":"2019","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","article-title":"EANM Practice Guideline for PET\/CT Imaging in Medullary Thyroid Carcinoma","volume":"47","author":"Giovanella","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0674","article-title":"Positron Emission Tomography Imaging in Medullary Thyroid Carcinoma: Time for Reappraisal","volume":"31","author":"Castinetti","year":"2021","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02930-8","article-title":"Imaging Medullary Thyroid Cancer Patients With Detectable Serum Markers: State of the Art and Future Perspectives","volume":"75","author":"Klain","year":"2022","journal-title":"Endocrine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2213-8587(15)00337-X","article-title":"Management of Advanced Medullary Thyroid Cancer","volume":"4","author":"Hadoux","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000336977","article-title":"European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer","volume":"1","author":"Schlumberger","year":"2012","journal-title":"Eur Thyroid J"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2017.04.009","article-title":"Chemotherapy and Tyrosine-Kinase Inhibitors for Medullary Thyroid Cancer","volume":"31","author":"Hadoux","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007958.pub2","article-title":"Angiogenesis-Inhibitors for Metastatic Thyroid Cancer","volume":"2010","author":"Tan","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/107327480200902S05","article-title":"Clinical Experience With Angiogenesis Signaling Inhibitors: Focus on Vascular Endothelial Growth Factor (VEGF) Blockers","volume":"9","author":"Rosen","year":"2002","journal-title":"Cancer Control"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.0417","article-title":"Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid Carcinoma","volume":"20","author":"Capp","year":"2010","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0132","article-title":"RET Mutation and Increased Angiogenesis in Medullary Thyroid Carcinomas","volume":"23","author":"Verrienti","year":"2016","journal-title":"Endocrine-Related Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in Progressive Medullary Thyroid Cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-Altered Thyroid Cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for Patients With Advanced or Metastatic RET-Altered Thyroid Cancer (ARROW): A Multi-Cohort, Open-Label, Registrational, Phase 1\/2 Study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell Signaling by Receptor Tyrosine Kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)00114-8","article-title":"Cell Signaling by Receptor Tyrosine Kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.742802","article-title":"A Review on the Therapeutic Role of Tkis in Case of CML in Combination With Epigenetic Drugs","volume":"12","author":"Amir","year":"2021","journal-title":"Front Genet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/1756287217713902","article-title":"Sunitinib in the Treatment of Renal Cell Carcinoma: An Update on Recent Evidence","volume":"9","author":"Rizzo","year":"2017","journal-title":"Ther Adv Urol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S174149","article-title":"Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date","volume":"13","author":"Tacconi","year":"2020","journal-title":"OncoTargets Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2021.109312","article-title":"Overview of Lenvatinib as a Targeted Therapy for Advanced Hepatocellular Carcinoma","volume":"7","author":"Rehman","year":"2021","journal-title":"Clin Exp Hepatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.752725","article-title":"Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials","volume":"11","author":"Mou","year":"2021","journal-title":"Front Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib Versus Placebo in Radioiodine-Refractory Thyroid Cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"New Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in Radioactive Iodine-Refractory, Locally Advanced or Metastatic Differentiated Thyroid Cancer: A Randomised, Double-Blind, Phase 3 Trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall Survival Analysis of EXAM, a Phase III Trial of Cabozantinib in Patients With Radiographically Progressive Medullary Thyroid Carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"key":"B71","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A Comprehensive Overview of the Role of the RET Proto-Oncogene in Thyroid Carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28661","article-title":"RET Gene Mutations (Genotype and Phenotype) of Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma","volume":"120","author":"Krampitz","year":"2014","journal-title":"Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1204","article-title":"Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update","volume":"98","author":"Wells","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/3.2.237","article-title":"Point Mutation Within the Tyrosine Kinase Domain of the RET Proto-Oncogene in Multiple Endocrine Neoplasia Type 2B and Related Sporadic Tumours","volume":"3","author":"Eng","year":"1994","journal-title":"Hum Mol Genet"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2016-103833","article-title":"New Insights in the Molecular Signature of Advanced Medullary Thyroid Cancer: Evidence of a Bad Outcome of Cases With Double RET Mutations","volume":"53","author":"Romei","year":"2016","journal-title":"J Med Genet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2703","article-title":"Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations in RET and RAS","volume":"98","author":"Agrawal","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.7815","article-title":"Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer","volume":"27","author":"Schlumberger","year":"2009","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0068","article-title":"Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer","volume":"28","author":"Lam","year":"2010","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3713","article-title":"A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H","volume":"99","author":"Bible","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0649","article-title":"A Phase II Trial of Imatinib Therapy for Metastatic Medullary Thyroid Carcinoma","volume":"92","author":"de Groot","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B81","article-title":"ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling, Angiogenesis, and Tumor Growth Following Oral Administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1100-03","article-title":"Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, With Additional Activity Against Epidermal Growth Factor Receptor Tyrosine Kinase","volume":"9","author":"Ciardiello","year":"2003","journal-title":"Clin Cancer Res: An Off J Am Assoc Cancer Res"},{"key":"B83","article-title":"ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M605604200","article-title":"Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain","volume":"281","author":"Knowles","year":"2006","journal-title":"J Biol Chem"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14395","article-title":"Drug Resistance Profiles of Mutations in the RET Kinase Domain","volume":"175","author":"Liu","year":"2018","journal-title":"Br J Pharmacol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13536","article-title":"Preclinical Characterization of Anlotinib, a Highly Potent and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor","volume":"109","author":"Xie","year":"2018","journal-title":"Cancer Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0137","article-title":"In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer","volume":"23","author":"Bentzien","year":"2013","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2017.06.001","article-title":"Protein Kinase Inhibitors for the Treatment of Advanced and Progressive Radiorefractory Thyroid Tumors: From the Clinical Trials to the Real Life","volume":"31","author":"Matrone","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02790","article-title":"Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial","volume":"38","author":"Kreissl","year":"2020","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0361","article-title":"Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results From a French Cohort","volume":"25","author":"Chougnet","year":"2015","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2020.687","article-title":"Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience","volume":"35","author":"Kim","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0206","article-title":"Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer","volume":"31","author":"Koehler","year":"2021","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B94","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-19-0259","article-title":"Medullary Thyroid Cancer Treated With Vandetanib: Predictors of a Longer and Durable Response","volume":"27","author":"Valerio","year":"2020","journal-title":"Endocrine-Related Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02426-x","article-title":"Long-Term Follow-Up and Safety of Vandetanib for Advanced Medullary Thyroid Cancer","volume":"71","author":"Ramos","year":"2021","journal-title":"Endocrine"},{"key":"B96","article-title":"Common Terminology Criteria for Adverse Events (CTCAE).V.5.0 [5x7]","year":"2017","journal-title":"Cancer Ther Eval Progr"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2017.04.012","article-title":"Management of Tyrosine Kinase Inhibitors (TKI) Side Effects in Differentiated and Medullary Thyroid Cancer Patients","volume":"31","author":"Resteghini","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1159\/000448919","article-title":"Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer","volume":"5","author":"Bastholt","year":"2016","journal-title":"Eur Thyroid J"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0258","article-title":"Safety and Efficacy of Two Starting Doses of Vandetanib in Advanced Medullary Thyroid Cancer","volume":"26","author":"Hu","year":"2019","journal-title":"Endocrine-Related Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0071","article-title":"Vandetanib in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma","volume":"19","author":"Fox","year":"2013","journal-title":"Clin Cancer Res: an Off J Am Assoc Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1301428","article-title":"Reversal of Cushing\u2019s Syndrome by Vandetanib in Medullary Thyroid Carcinoma","volume":"369","author":"Baudry","year":"2013","journal-title":"New Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4340","article-title":"Vandetanib Successfully Controls Medullary Thyroid Cancer-Related Cushing Syndrome in an Adolescent Patient","volume":"99","author":"Nella","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1590\/2359-3997000000057","article-title":"Rapid Response of Hypercortisolism to Vandetanib Treatment in a Patient With Advanced Medullary Thyroid Cancer and Ectopic Cushing Syndrome","volume":"59","author":"Pitoia","year":"2015","journal-title":"Arch Endocrinol Metab"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0334","article-title":"Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma With a Somatic RET Mutation","volume":"27","author":"Paepegaey","year":"2017","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30252","article-title":"Correlative Analyses of RET and RAS Mutations in a Phase 3 Trial of Cabozantinib in Patients With Progressive, Metastatic Medullary Thyroid Cancer","volume":"122","author":"Sherman","year":"2016","journal-title":"Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ20-0171","article-title":"Comparative Efficacy and Safety of Tyrosine Kinase Inhibitors for Thyroid Cancer: A Systematic Review and Meta-Analysis","volume":"67","author":"Oba","year":"2020","journal-title":"Endocrine J"},{"key":"B108","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.semcancer.2020.12.008","article-title":"Effects of Tyrosine Kinase Inhibitors on Thyroid Function and Thyroid Hormone Metabolism","volume":"79","author":"Basolo","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ctrv.2018.04.007","article-title":"Management of Treatment-Related Toxicities in Advanced Medullary Thyroid Cancer","volume":"66","author":"Brose","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B110","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40618-020-01272-y","article-title":"Proteinuria Is a Late-Onset Adverse Event in Patients Treated With Cabozantinib","volume":"44","author":"Cappagli","year":"2021","journal-title":"J Endocrinological Invest"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease Associated Mutations at Valine 804 in the RET Receptor Tyrosine Kinase Confer Resistance to Selective Kinase Inhibitors","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4665","article-title":"AMG 706, an Oral, Multikinase Inhibitor That Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts","volume":"66","author":"Polverino","year":"2006","journal-title":"Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2015.16.16.7089","article-title":"High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma","volume":"16","author":"Dunna","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF\/MEK\/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic-Pharmacodynamic Correlation From Mouse to Human With Pazopanib, a Multikinase Angiogenesis Inhibitor With Potent Antitumor and Antiangiogenic Activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"B116","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin Cancer Res: An Off J Am Assoc Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01491-3","article-title":"Lenvatinib as a Salvage Therapy for Advanced Metastatic Medullary Thyroid Cancer","volume":"44","author":"Matrone","year":"2021","journal-title":"J Endocrinological Invest"},{"key":"B118","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: A Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib Inhibits Angiogenesis via Suppressing the Activation of VEGFR2, Pdgfrbeta and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"B120","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, Pharmacokinetics, and Antitumor Properties of Anlotinib, an Oral Multi-Target Tyrosine Kinase Inhibitor, in Patients With Advanced Refractory Solid Tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0022","article-title":"Anlotinib for the Treatment of Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer","volume":"28","author":"Sun","year":"2018","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2950","article-title":"Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res: An Off J Am Assoc Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605056","article-title":"Correlation of RET Somatic Mutations With Clinicopathological Features in Sporadic Medullary Thyroid Carcinomas","volume":"100","author":"Moura","year":"2009","journal-title":"Br J Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2007.12.016","article-title":"Somatic Mutations in the RET Proto-Oncogene in Sporadic Medullary Thyroid Carcinomas","volume":"284","author":"Dvorakova","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23986","article-title":"RET Mutation Heterogeneity in Primary Advanced Medullary Thyroid Cancers and Their Metastases","volume":"9","author":"Romei","year":"2018","journal-title":"Oncotarget"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211019675","article-title":"Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer (SIREN): A Retrospective Analysis of Patients Treated Through an Access Program","volume":"13","author":"Illini","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3680","article-title":"RET Revisited: Expanding the Oncogenic Portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0528","article-title":"RET Signaling in Prostate Cancer","volume":"23","author":"Ban","year":"2017","journal-title":"Clin Cancer Res: An Off J Am Assoc Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgz184","article-title":"Retoma: A Cancer Subtype With a Shared Driver Oncogene","volume":"41","author":"Kohno","year":"2020","journal-title":"Carcinogenesis"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0329","article-title":"Hallmarks of RET and Co-Occuring Genomic Alterations in RET-Aberrant Cancers","volume":"20","author":"Adashek","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2016.04.023","article-title":"Elevated RET Expression Enhances EGFR Activation and Mediates EGFR Inhibitor Resistance in Head and Neck Squamous Cell Carcinoma","volume":"377","author":"Lin","year":"2016","journal-title":"Cancer Lett"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.225","article-title":"RET Is a Potential Tumor Suppressor Gene in Colorectal Cancer","volume":"32","author":"Luo","year":"2013","journal-title":"Oncogene"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.483","article-title":"Upregulation of RET Induces Perineurial Invasion of Pancreatic Adenocarcinoma","volume":"36","author":"Amit","year":"2017","journal-title":"Oncogene"},{"key":"B135","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity With Vascular Endothelial Growth Factor Inhibitor Therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET Kinase Inhibition for Patients With RET-Altered Cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision Targeted Therapy With BLU-667 for RET-Driven Cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy188","article-title":"The Right Compound for the Right Target: Tackling RET","volume":"29","author":"Seoane","year":"2018","journal-title":"Ann Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"New Engl J Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00096","article-title":"Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases","volume":"4","author":"Andreev-Drakhlin","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1987","article-title":"Significant Response of Medullary Thyroid Cancer Choroidal Metastases to Highly Selective RET Inhibitor Selpercatinib: A Case Report","volume":"32","author":"Matrone","year":"2021","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"key":"B142","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1002\/hed.26527","article-title":"Neoadjuvant Selpercatinib for Advanced Medullary Thyroid Cancer","volume":"43","author":"Jozaghi","year":"2021","journal-title":"Head Neck"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00401","article-title":"Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations","volume":"4","author":"Ortiz","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural Basis of Acquired Resistance to Selpercatinib and Pralsetinib Mediated by Non-Gatekeeper RET Mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small-Cell Lung Cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"key":"B147","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/1078-0432.CCR-20-2278","article-title":"Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients With RET Fusion-Positive Lung Cancer by Combining Selpercatinib With Crizotinib","volume":"27","author":"Rosen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.142547","article-title":"Targeting G1\/s Phase Cell-Cycle Genomic Alterations and Accompanying Co-Alterations With Individualized CDK4\/6 Inhibitor-Based Regimens","volume":"6","author":"Kato","year":"2021","journal-title":"JCI Insight"},{"key":"B149","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-World Data From a Molecular Tumor Board Demonstrates Improved Outcomes With a Precision N-of-One Strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"key":"B150","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.trecan.2020.08.009","article-title":"From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm","volume":"7","author":"Adashek","year":"2021","journal-title":"Trends Cancer"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.010","article-title":"Patient-Driven Discovery and Post-Clinical Validation of NTRK3 Fusion as an Acquired Resistance Mechanism to Selpercatinib in RET Fusion-Positive Lung Cancer","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in Patients With Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"New Engl J Med"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3616","article-title":"The Next-Generation RET Inhibitor TPX-0046 Is Active in Drug-Resistant and Na\u00efve RET-Driven Cancer Models","volume":"38","author":"Drilon","year":"2020","journal-title":"J Clin Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02167","article-title":"Targeting Rearranged During Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development","volume":"64","author":"Saha","year":"2021","journal-title":"J Med Chem"},{"key":"B156","doi-asserted-by":"publisher","first-page":"TPS3162","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3162","article-title":"A Phase I Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer and Medullary Thyroid Cancer","volume":"37","author":"Schoffski","year":"2019","journal-title":"J Clin Oncol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3008","article-title":"BOS172738, a Highly Potent and Selective RET Inhibitor, for the Treatment of RET-Altered Tumors Including RET-Fusion+ NSCLC and RET-Mutant MTC: Phase 1 Study Results","volume":"39","author":"Schoffski","year":"2021","journal-title":"J Clin Oncol"},{"key":"B158","volume-title":"Stemline in-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline. Vol 20212019","year":"2019"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1159\/000346174","article-title":"2012 European Thyroid Association Guidelines for Genetic Testing and its Clinical Consequences in Medullary Thyroid Cancer","volume":"1","author":"Elisei","year":"2013","journal-title":"Eur Thyroid J"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1677\/JME-09-0024","article-title":"Molecular Genetics of Medullary Thyroid Carcinoma: The Quest for Novel Therapeutic Targets","volume":"43","author":"Cerrato","year":"2009","journal-title":"J Mol Endocrinol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2010.03900.x","article-title":"RET Genetic Screening of Sporadic Medullary Thyroid Cancer (MTC) Allows the Preclinical Diagnosis of Unsuspected Gene Carriers and the Identification of a Relevant Percentage of Hidden Familial MTC (FMTC)","volume":"74","author":"Romei","year":"2011","journal-title":"Clin Endocrinol"},{"key":"B162","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Thyroid Carcinoma. Vol 2022. Version 3.2021 Ed","author":"Haddad","year":"2021"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.021","article-title":"ESMO Recommendations on the Standard Methods to Detect RET Fusions and Mutations in Daily Practice and Clinical Research","volume":"32","author":"Belli","year":"2021","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01039","article-title":"Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma","volume":"102","author":"Cote","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.708949","article-title":"Update on Targeted Therapy in Medullary Thyroid Cancer","volume":"12","author":"Okafor","year":"2021","journal-title":"Front Endocrinol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/2041104b0","article-title":"An Unidentified Virus Which Causes the Rapid Production of Tumours in Mice","volume":"204","author":"Harvey","year":"1964","journal-title":"Nature"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/292506a0","article-title":"The P21 Src Genes of Harvey and Kirsten Sarcoma Viruses Originate From Divergent Members of a Family of Normal Vertebrate Genes","volume":"292","author":"Ellis","year":"1981","journal-title":"Nature"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3106","article-title":"RAS Oncogenes: Weaving a Tumorigenic Web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4389","article-title":"Drugging the Undruggable RAS: Mission Possible","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-Targeted Therapies: Is the Undruggable Drugged","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0958","article-title":"Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas","volume":"19","author":"Gilardi","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-2422","article-title":"Medullary Thyroid Cancer: Targeting the RET Kinase Pathway With Sorafenib\/Tipifarnib","volume":"7","author":"Hong","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"B173","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1210\/jc.2010-1899","article-title":"Inhibition of the Ras\/Raf\/MEK\/ERK and RET Kinase Pathways With the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies","volume":"96","author":"Hong","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2017.04.013","article-title":"The Molecular Basis for RET Tyrosine-Kinase Inhibitors in Thyroid Cancer","volume":"31","author":"De Falco","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B175","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in Cancer: Mechanisms and Advances in Clinical Trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol Cancer"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2700","article-title":"Activation of the Mtor Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases","volume":"18","author":"Tamburrino","year":"2012","journal-title":"Clin Cancer Res: An Off J Am Assoc Cancer Res"},{"key":"B177","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.mce.2009.09.027","article-title":"The Rapamycin-Derivative RAD001 (Everolimus) Inhibits Cell Viability and Interacts With the Akt-Mtor-P70s6k Pathway in Human Medullary Thyroid Carcinoma Cells","volume":"315","author":"Grozinsky-Glasberg","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04296.x","article-title":"Preliminary Report of the Use of Everolimus in a Patient With Progressive Medullary Thyroid Carcinoma","volume":"77","author":"Druce","year":"2012","journal-title":"Clin Endocrinol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/348124","article-title":"Beneficial Effects of the Mtor Inhibitor Everolimus in Patients With Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial","volume":"2015","author":"Schneider","year":"2015","journal-title":"Int J Endocrinol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2297","article-title":"Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-Refractory Thyroid Cancer: A Phase II Study","volume":"24","author":"Hanna","year":"2018","journal-title":"Clin Cancer Res: An Off J Am Assoc Cancer Res"},{"key":"B181","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s12020-018-1583-7","article-title":"The Antiproliferative Effect of Pasireotide LAR Alone and in Combination With Everolimus in Patients With Medullary Thyroid Cancer: A Single-Center, Open-Label, Phase II, Proof-of-Concept Study","volume":"62","author":"Faggiano","year":"2018","journal-title":"Endocrine"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0334","article-title":"Selective Activation of Somatostatin Receptor Subtypes Differentially Modulates Secretion and Viability in Human Medullary Thyroid Carcinoma Primary Cultures: Potential Clinical Perspectives","volume":"91","author":"Zatelli","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.07.009","article-title":"Notch Signaling in the Tumor Microenvironment","volume":"34","author":"Meurette","year":"2018","journal-title":"Cancer Cell"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.149","article-title":"Erbb-2 Inhibition Activates Notch-1 and Sensitizes Breast Cancer Cells to a Gamma-Secretase Inhibitor","volume":"27","author":"Osipo","year":"2008","journal-title":"Oncogene"},{"key":"B185","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1158\/1535-7163.MCT-14-0073","article-title":"Tumor-Suppressor Role of Notch3 in Medullary Thyroid Carcinoma Revealed by Genetic and Pharmacological Induction","volume":"14","author":"Jaskula-Sztul","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2017.07.039","article-title":"Notch3 as a Novel Therapeutic Target in Metastatic Medullary Thyroid Cancer","volume":"163","author":"Lou","year":"2018","journal-title":"Surgery"},{"key":"B187","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: An Emerging Target in Small Cell Lung Cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0611","article-title":"DLL3 (Delta-Like Protein 3) Expression Correlates With Stromal Desmoplasia and Lymph Node Metastases in Medullary Thyroid Carcinomas","volume":"10","author":"Ingenwerth","year":"2021","journal-title":"Endocrine Connections"},{"key":"B189","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41698-021-00214-y","article-title":"A Phase I\/II Study of Rovalpituzumab Tesirine in Delta-Like 3-Expressing Advanced Solid Tumors","volume":"5","author":"Mansfield","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome Inhibitors in Cancer Therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010816.pub2","article-title":"Bortezomib for the Treatment of Multiple Myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2472","article-title":"Antitumor Effects of the Proteasome Inhibitor Bortezomib in Medullary and Anaplastic Thyroid Carcinoma Cells","volume":"91","author":"Mitsiades","year":"2006","journal-title":"Vitro J Clin Endocrinol Metab"},{"key":"B193","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1634\/theoncologist.2018-0452","article-title":"Phase I\/II Trial of Vandetanib and Bortezomib in Adults With Locally Advanced or Metastatic Medullary Thyroid Cancer","volume":"24","author":"Del Rivero","year":"2019","journal-title":"Oncologist"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-200106000-00011","article-title":"Radiopeptide Transmitted Internal Irradiation of Non-Iodophil Thyroid Cancer and Conventionally Untreatable Medullary Thyroid Cancer Using","volume":"22","author":"Waldherr","year":"2001","journal-title":"Nucl Med Commun"},{"key":"B195","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/108497804773391694","article-title":"Receptor Radionuclide Therapy With 90Y-DOTATOC in Patients With Medullary Thyroid Carcinomas","volume":"19","author":"Bodei","year":"2004","journal-title":"Cancer Biother Radiopharmaceuticals"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0935","article-title":"Response to [90Yttrium-DOTA]-TOC Treatment Is Associated With Long-Term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial","volume":"13","author":"Iten","year":"2007","journal-title":"Clin Cancer Res: An Off J Am Assoc Cancer Res"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000000628","article-title":"Is There a Role for Peptide Receptor Radionuclide Therapy in Medullary Thyroid Cancer","volume":"40","author":"Vaisman","year":"2015","journal-title":"Clin Nucl Med"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26024","article-title":"Clinical Utility of (177) Lu-DOTATATE PRRT in Somatostatin Receptor-Positive Metastatic Medullary Carcinoma of Thyroid Patients With Assessment of Efficacy, Survival Analysis, Prognostic Variables, and Toxicity","volume":"42","author":"Parghane","year":"2020","journal-title":"Head Neck"},{"key":"B199","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12885-021-08257-x","article-title":"Efficacy and Safety of Peptide Receptor Radionuclide Therapy in Advanced Radioiodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Thyroid Cancer: A Systematic Review","volume":"21","author":"Maghsoomi","year":"2021","journal-title":"BMC Cancer"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab588","article-title":"Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET\/CT and Peptide Receptor Radionuclide Therapy","volume":"106","author":"Hayes","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2140","article-title":"A Novel Therapeutic Strategy for Medullary Thyroid Cancer Based on Radioiodine Therapy Following Tissue-Specific Sodium Iodide Symporter Gene Expression","volume":"90","author":"Cengic","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B202","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3109\/02841868609136405","article-title":"Evidence of C-Cell Destruction in the Thyroid Gland of Mice Exposed to High 131I Doses","volume":"25","author":"Feinstein","year":"1986","journal-title":"Acta Radiol Oncol"},{"key":"B203","article-title":"Effects of Radiation on Parafollicular C Cells of the Thyroid Gland","volume":"94","author":"Shah","year":"1983","journal-title":"Surgery"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnm.0000202860.30274.e4","article-title":"Radioactive Iodine Treatment in Medullary Thyroid Carcinoma","volume":"27","author":"Faik Erdogan","year":"2006","journal-title":"Nucl Med Commun"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-48-3-451","article-title":"Radioiodine in the Treatment of Medullary Carcinoma of the Thyroid","volume":"48","author":"Hellman","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0943","article-title":"Radioactive Iodine in the Treatment of Medullary Thyroid Carcinoma: A Controlled Multicenter Study","volume":"168","author":"Meijer","year":"2013","journal-title":"Eur J Endocrinol\/European Fed Endocrine Societies"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B208","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing Immunotherapy in Cancer by Targeting Emerging Immunomodulatory Pathways","volume":"19","author":"Kraehenbuehl","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197511)36:5<1658::aid-cncr2820360519>3.0.co;2-0","article-title":"Medullary Carcinoma of the Thyroid. Cellular Immune Response to Tumor Antigen in a Heritable Human Cancer","volume":"36","author":"George","year":"1975","journal-title":"Cancer"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197704142961502","article-title":"Cellular Immune Responses in Familial Medullary Thyroid Carcinoma","volume":"296","author":"Rocklin","year":"1977","journal-title":"New Engl J Med"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0104","article-title":"Very Low Expression of PD-L1 in Medullary Thyroid Carcinoma","volume":"24","author":"Bongiovanni","year":"2017","journal-title":"Endocrine-Related Cancer"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.10.060","article-title":"PD-1\/PD-L1 Expressions in Medullary Thyroid Carcinoma: Clinicopathologic and Prognostic Analysis of Chinese Population","volume":"45","author":"Bi","year":"2019","journal-title":"Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa701","article-title":"Immune Co-Inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study","volume":"106","author":"Shi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0604","article-title":"Comprehensive Immune Profiling of Medullary Thyroid Cancer","volume":"30","author":"Pozdeyev","year":"2020","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00490","article-title":"A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer","volume":"11","author":"Del Rivero","year":"2020","journal-title":"Front Endocrinol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"e000799","DOI":"10.1136\/esmoopen-2020-000799","article-title":"Responsiveness to Immune Checkpoint Inhibitors Versus Other Systemic Therapies in RET-Aberrant Malignancies","volume":"5","author":"Hegde","year":"2020","journal-title":"ESMO Open"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.864253\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T08:36:30Z","timestamp":1648629390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.864253\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":216,"alternative-id":["10.3389\/fendo.2022.864253"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.864253","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]},"article-number":"864253"}}